Spots Global Cancer Trial Database for Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy

Official Title: High-Dose Cyclophosphamide for the Treatment of Severe Autoimmune Enteropathy

Study ID: NCT00258180

Conditions

Diarrhea

Gastrointestinal Complications

Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

filgrastim

cyclophosphamide

Study Description

Brief Summary: RATIONALE: Cyclophosphamide may help control the symptoms of autoimmune enteropathy . PURPOSE: This phase II trial is studying how well cyclophosphamide works in treating young patients with severe autoimmune enteropathy.

Detailed Description: OBJECTIVES: Primary * Determine the rate of treatment-free remission in young patients with severe autoimmune enteropathy treated with high-dose cyclophosphamide. Secondary * Determine the toxic effects of this drug in these patients. OUTLINE: Patients receive cyclophosphamide IV over 1 hour on days 1-4. Patients then receive filgrastim (G-CSF) IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover. After completion of study treatment, patients are followed periodically for up to 1½ years. PROJECTED ACCRUAL: A total of 7-11 patients will be accrued for this study.